Granulocyte Colony-Stimulating Factor for Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung Cancer

This publication has 22 references indexed in Scilit:

• Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy
  Value in Health, 2005
• Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study
  Journal of Clinical Oncology, 2004
• Effects of Indirect and Additional Direct Costs on the Risk Threshold for Prophylaxis with Colony‐Stimulating Factors in Patients at Risk for Severe Neutropenia from Cancer Chemotherapy
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004
• G-CSF as prophylaxis of febrile neutropenia in SCLC
  Expert Opinion on Pharmacotherapy, 2002
• Assessing the Value of a New Pharmaceutical
  Medical Care, 1998
• G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation
  Journal of Clinical Pharmacy & Therapeutics, 1996
• Economic Evaluation of Lenograstim for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung Cancer
  PharmacoEconomics, 1994
• The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
  European Journal Of Cancer, 1993
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
  European Journal Of Cancer, 1993
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
  New England Journal of Medicine, 1991